Thioredoxin Reductase and Organometallic Complexes: A Pivotal System to Tackle Multidrug Resistant Tumors?

Cancers (Basel). 2023 Sep 6;15(18):4448. doi: 10.3390/cancers15184448.

Abstract

Cancers classified as multidrug-resistant (MDR) are a family of diseases with poor prognosis despite access to increasingly sophisticated treatments. Several mechanisms explain these resistances involving both tumor cells and their microenvironment. It is now recognized that a multi-targeting approach offers a promising strategy to treat these MDR tumors. Inhibition of thioredoxin reductase (TrxR), a key enzyme in maintaining redox balance in cells, is a well-identified target for this approach. Auranofin was the first inorganic gold complex to be described as a powerful inhibitor of TrxR. In this review, we will first recall the main results obtained with this metallodrug. Then, we will focus on organometallic complexes reported as TrxR inhibitors. These include gold(I), gold(III) complexes and metallocifens, i.e., organometallic complexes of Fe and Os derived from tamoxifen. In these families of complexes, similarities and differences in the molecular mechanisms of TrxR inhibition will be highlighted. Finally, the possible relationship between TrxR inhibition and cytotoxicity will be discussed and put into perspective with their mode of action.

Keywords: N-heterocyclic carbene; auranofin; cancer; ferrocene; gold; organometallic complexes; thioredoxin reductase.

Publication types

  • Review

Grants and funding

This research was funded by National Agency of Research (ANR): FERROTHIORED (ANR-21-PRRD-0038-01) and NaTeMOc projects (ANR-19-CE18–0022), France Relance programme and Feroscan (dispositive 4; C21/1165).